Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company continues to expand in international markets with the signing of a distributor for the Dominican Republic for the LuViva® Advanced Cervical Scan.

“We continue to focus on markets that need a better way of screening for cervical cancer,” said Gene Cartwright, CEO and President of Guided Therapeutics, Inc. “Countries like the Dominican Republic, with about 3.3 million women of screening age, provide significant opportunities for the company to work with the government and grow LuViva sales. Visibility into the pipeline for LuViva supports our expectation for 2016 sales of $3 million to $5 million.”

According to the American Association for Cancer Research, “Latin America and the Caribbean have one of the highest incidence and mortality rates from cervical cancer in the world,” with age-adjusted incidence rates ranging from 20 to 80 per 100,000 women annually.

Growing International Momentum for LuViva

The company also recently announced shipments of the LuViva Advanced Cervical Scan to Indonesia, Bangladesh, Bulgaria and Nigeria — all countries that are targeted for screening.

On January 28, the Company announced that the Nairobi County Health Services Sector had agreed to purchase an additional five LuViva Advanced Cervical Scans for use in the agency’s cervical cancer screening program. The following headlines link to LuViva stories in the media:

Kenya set to benefit from new Cancer Screening Machines

Nairobi orders second batch of cancer equipment

Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB:GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.

Links in this news release: http://www.newsghana.com.gh/kenya-set-to-benefit-from-new-cancer-screening-machines/ and http://www.businessdailyafrica.com/Nairobi-County-orders-second-batch-of-cancer-equipment-/-/539552/3059620/-/p0x87fz/-/index.html


Contacts

IRTH Communications
Robert Haag, 866-976-4784
Managing Partner
gthp@irthcommunications.com
or
Guided Therapeutics, Inc.
Bill Wells, 770-242-8723